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Introduction
Despite a signiﬁ cant increase in our understanding of the 
pathogenesis of Alzheimer’s disease (AD) over the past 
two decades, the therapeutic options are still very 
modest. Cholinesterase inhibitors and the N-methyl-d-
aspartate receptor agonists currently available have a 
modest clinical eﬀ ect but do not intervene with the 
underlying pathophysiology [1]. Th e ultimate aim of AD 
therapy is to stop or slow down the underlying disease 
process.
Recently the ﬁ rst two large trials with drugs that may 
slow disease progression have been published: a phase 2, 
passive immunization trial with bapineuzumab; and a 
phase 3 trial with tarenﬂ urbil, a modulator of γ-secretase. 
Both drugs supposedly interfere with β-amyloid (Aβ) 
metabolism. Abnormalities in Aβ processing are thought 
to be central in AD pathophysiology according to the 
amyloid cascade hypothesis. Th e mode of action of 
bapineuzumab is to remove aggregated Aβ, while 
tarenﬂ urbil decreases the production of the pathogenic 
Aβ42 peptide. In the present commentary, we discuss the 
results of these trials and the implications for future 
therapy and insight into AD pathophysiology.
The amyloid cascade
Th e amyloid hypothesis has led to an understanding of 
the pathology of AD, and also provides a basis for novel 
drug development. Th is hypothesis suggests that 
increased Aβ42 production and subsequent aggregation 
in limbic and association cortices leads to synaptic 
changes and causes deposition of Aβ42 in diﬀ use plaques, 
which in turn causes microglial and astrocytic activation. 
As a result, altered neuronal homeostasis and oxidative 
injury lead to tangle formation, and eventually to 
neuronal and synaptic dysfunction and selective neuronal 
loss [2,3]. Th e most important implied prediction of the 
hypothesis is that reduction of Aβ aggregation would 
ameliorate AD symptoms.
Th ree methods for intervening in the amyloid cascade 
have thus far been tested in clinical trials: active immuni-
zation, passive immunization, and modulation of γ-
secretase [4,5]. In this light we shall discuss the two 
recent clinical trials mentioned above: the phase 2 trial 
with bapineuzumab, and the phase 3 trial with 
taren ﬂ urbil.
Bapineuzumab
Bapineuzumab is a humanized anti-Aβ monoclonal anti-
body. Preclinical passive immunotherapy studies with 
monoclonal anti-Aβ antibodies in a mouse model of AD 
showed antibody binding to Aβ plaques, reduction in Aβ 
plaque burden, and reversal of memory defects [6,7]. 
Bapineuzumab is directed against the N-terminus of Aβ 
and is hypothesized to bind to Aβ in the brain and to 
facilitate its removal.
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Alzheimer’s disease.
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Th e recently published phase 2 multiple-ascending-dose 
trial in mild to moderate AD tested the safety and eﬃ  cacy 
of bapineuzumab [8]. Two hundred and thirty-four AD 
patients were randomly assigned to intravenous bapineu-
zu mab (n = 124) or to placebo (n = 110) in four dose 
cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received six 
infusions, 13 weeks apart, with ﬁ nal assessments 18 
months later. Th e primary eﬃ  cacy analysis compared 
treatment diﬀ erences within dose cohorts on the 
Alzheimer’s Disease Assessment Scale for Cognition and 
on the Disability Assessment for Dementia. No signiﬁ cant 
diﬀ erences were found in the primary eﬃ  cacy analysis.
Exploratory analyses, however, showed potential 
treatment diﬀ erences on cognitive and functional end-
points in study completers and apolipoprotein E (APOE) 
ε4 noncarriers. In this subgroup, subjects on active treat-
ment showed 5 points less decline on the Alzheimer’s 
Disease Assessment Scale for Cognition after 78 weeks 
compared with placebo. A safety concern was the 
occurrence of reversible vasogenic edema, detected on 
brain magnetic resonance imaging in 10% of the 
bapineuzumab-treated patients. Vasogenic edema was 
more frequent in APOE ε4 carriers, which may suggest 
that vasogenic edema is related to vascular amyloid 
burden since APOE ε4 carriers show more vascular 
amyloid deposition.
Th e potential treatment diﬀ erences in the exploratory 
analyses have led to the evaluation of bapineuzumab in a 
phase 3 trial that started in December 2007, which will 
take possible treatment diﬀ erences by APOE ε4 status 
into consideration. Meanwhile, a recent publication 
showed that treatment with bapineuzumab for 78 weeks 
reduced ﬁ brillar amyloid burden in subjects with AD, 
shown by Pittsburgh compound B positron emission 
tomography ((PiB-PET) [9].
Tarenfl urbil
Tarenﬂ urbil is a modulator of the activity of γ-secretase, 
and may for that reason act as an Aβ42 lowering agent. In 
mouse models of AD, tarenﬂ urbil prevents learning and 
memory deﬁ cits and reduces Aβ42 brain concentrations 
[10]. In an earlier phase 2 trial in 210 AD patients, mildly 
aﬀ ected patients (baseline mini-mental state examination 
20 to 26), who received 800 mg tarenﬂ urbil twice per day, 
had lower rates of decline in activities of daily living and 
global function compared with subjects who received 
placebo [11].
Th ese results led to a large multicentre, phase 3, 
randomized, double-blind, placebo-controlled trial for 
the evaluation of the eﬃ  cacy, safety, and tolerability of 
tarenﬂ urbil in 1,684 subjects with mild AD (mini-mental 
state examination 15 to 26) [12]. Initially, patients were 
assigned to treatment with tarenﬂ urbil at doses of either 
400 or 800 mg twice daily or placebo. After an analysis of 
phase 2 data indicated that subjects had the strongest 
response to 800 mg tarenﬂ urbil twice daily, however, the 
400  mg dose was ended. Th e main outcome measures 
were the change from baseline to 18 months score on the 
Alzheimer’s Disease Assessment Scale for Cognition and 
on the Alzheimer’s Disease Cooperative Study – 
Activities of Daily Living scale. Tarenﬂ urbil had no 
beneﬁ cial eﬀ ect on the primary or secondary outcomes. 
Th e APOE genotype had no eﬀ ect on treatment response. 
Th e tarenﬂ urbil group had a small increase in frequency 
of dizziness, anemia, and infections.
Discussion
What have these two trials taught us? Th e bapineuzumab 
trial showed that intravenous administration of the serial 
bapineuzumab doses is feasible and, as long as the 
possible occurrence of vasogenic edema is monitored, is 
relatively safe. Th e positron emission tomography 
substudy provided the suggestion that bapineu zu mab 
indeed reduces amyloid load in vivo. Th e lack of eﬀ ect on 
the primary endpoint of the trial may be due to the fact 
that, as the authors point out, it was underpowered to 
show small diﬀ erences in eﬃ  cacy. Indeed, a larger sample 
size would have increased the ability to detect statistically 
signiﬁ cant diﬀ erences, but this does not alter the notion 
that clinical eﬀ ects may still be small and of limited 
relevance. In the case of the tarenﬂ urbil trial, it is possible 
that the dose of 800 mg twice daily was still too low. Th e 
discrepant ﬁ ndings between the phase 2 subgroup 
analyses and the phase 3 study strongly caution against 
apparent overinter pre tation of post hoc analyses.
Th e ﬁ ndings may also have implications for the amyloid 
hypothesis. First, it is possible that the relation between 
amyloid processing and AD is modiﬁ ed by the APOE 
genotype, and in this respect it will be interesting to see 
how a possible treatment eﬀ ect may diﬀ er by APOE ε4 
status in the new phase 3 bapineuzumab study. It stresses 
again how important APOE is in several aspects of AD 
[13,14].
Second, as reduction of Aβ42 was not eﬀ ective and 
removal of aggregated Aβ had a limited eﬀ ect, other Aβ 
species may be the main toxic agent in AD or the AD 
pathology may not depend on Aβ. Alternative models for 
AD pathophysiology may better explain how accumu-
lation of Aβ42 leads to tangle formation, and why tangle 
formation is closer to neuronal cell death than amyloid 
accumulation [2].
Th ird, reduction of Aβ production or removal of Aβ 
may not be successful in patients who already have a 
substantial amyloid burden if the cascade becomes 
independent of amyloid burden once Aβ42 accumulation 
has set oﬀ  an irreversible chain of events.
Finally, the amyloid hypothesis neglects the role of 
cerebrovascular damage, which is typically comorbid in 
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older patients with AD, and may be a crucial cofactor in 
causing neurodegeneration and may interact with the 
pathology of AD [15]. Cerebrovascular damage is a factor 
that may have to be taken into account when developing 
new therapeutic strategies for AD.
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